IL321560A - Treatment of autoimmune disease - Google Patents
Treatment of autoimmune diseaseInfo
- Publication number
- IL321560A IL321560A IL321560A IL32156025A IL321560A IL 321560 A IL321560 A IL 321560A IL 321560 A IL321560 A IL 321560A IL 32156025 A IL32156025 A IL 32156025A IL 321560 A IL321560 A IL 321560A
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- autoimmune disease
- autoimmune
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263476066P | 2022-12-19 | 2022-12-19 | |
| PCT/EP2023/086487 WO2024133161A1 (en) | 2022-12-19 | 2023-12-18 | Treatment of autoimmune disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL321560A true IL321560A (en) | 2025-08-01 |
Family
ID=89474788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL321560A IL321560A (en) | 2022-12-19 | 2025-06-17 | Treatment of autoimmune disease |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240199761A1 (en) |
| EP (1) | EP4638507A1 (en) |
| JP (1) | JP2025542239A (en) |
| KR (1) | KR20250124877A (en) |
| CN (1) | CN120476150A (en) |
| AR (1) | AR131398A1 (en) |
| AU (1) | AU2023413552A1 (en) |
| CL (1) | CL2025001822A1 (en) |
| CO (1) | CO2025009742A2 (en) |
| CR (1) | CR20250284A (en) |
| IL (1) | IL321560A (en) |
| MX (1) | MX2025007229A (en) |
| TW (1) | TW202444762A (en) |
| WO (1) | WO2024133161A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024406222A1 (en) | 2023-12-20 | 2026-06-04 | Bristol-Myers Squibb Company | Antibodies targeting il-18 receptor beta (il-18rβ) and related methods |
| WO2026020127A2 (en) | 2024-07-19 | 2026-01-22 | Bristol-Myers Squibb Company | Methods of assessing citrullination and activity of pad2 modulators |
| WO2026136763A1 (en) | 2024-12-19 | 2026-06-25 | Bristol-Myers Squibb Company | Genetic predictor for il18 driven disease |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| AT503889B1 (en) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | MULTIVALENT IMMUNE LOBULINE |
| JPWO2012026309A1 (en) * | 2010-08-23 | 2013-10-28 | 公立大学法人横浜市立大学 | Creation of anti-PAD4 antibody drugs |
| JP6057299B2 (en) | 2011-10-31 | 2017-01-11 | 国立大学法人 長崎大学 | Preventive or therapeutic agent for viral infection |
| CA2871934C (en) | 2012-04-30 | 2023-06-13 | Medimmune, Llc | Molecules with reduced effector function and extended half-lives, compositions, and uses thereof |
| US20150376294A1 (en) | 2012-12-03 | 2015-12-31 | Rigshospitalet | Anti-pad2 antibodies and treatment of autoimmune diseases |
| AU2014374055B2 (en) | 2013-12-30 | 2018-11-08 | Epimab Biotherapeutics Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| JP6832709B2 (en) | 2014-05-16 | 2021-02-24 | メディミューン,エルエルシー | Molecules with modified neonatal Fc receptor binding for enhanced therapeutic and diagnostic properties |
| US11447569B2 (en) | 2015-03-06 | 2022-09-20 | Public University Corporation Yokohama City University | Anti-PAD4 antibody |
| WO2016155745A1 (en) | 2015-03-27 | 2016-10-06 | Rigshospitalet | Cross-reactive anti-pad antibodies |
| AR124914A1 (en) | 2021-02-18 | 2023-05-17 | Mitsubishi Tanabe Pharma Corp | NEW ANTI-PAD4 ANTIBODY |
-
2023
- 2023-12-18 AR ARP230103431A patent/AR131398A1/en unknown
- 2023-12-18 JP JP2025536094A patent/JP2025542239A/en active Pending
- 2023-12-18 US US18/542,918 patent/US20240199761A1/en active Pending
- 2023-12-18 WO PCT/EP2023/086487 patent/WO2024133161A1/en not_active Ceased
- 2023-12-18 TW TW112149254A patent/TW202444762A/en unknown
- 2023-12-18 EP EP23836387.3A patent/EP4638507A1/en active Pending
- 2023-12-18 CR CR20250284A patent/CR20250284A/en unknown
- 2023-12-18 CN CN202380087342.9A patent/CN120476150A/en active Pending
- 2023-12-18 KR KR1020257024251A patent/KR20250124877A/en active Pending
- 2023-12-18 AU AU2023413552A patent/AU2023413552A1/en active Pending
-
2025
- 2025-06-17 IL IL321560A patent/IL321560A/en unknown
- 2025-06-18 CL CL2025001822A patent/CL2025001822A1/en unknown
- 2025-06-19 MX MX2025007229A patent/MX2025007229A/en unknown
- 2025-07-17 CO CONC2025/0009742A patent/CO2025009742A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2025001822A1 (en) | 2025-10-03 |
| JP2025542239A (en) | 2025-12-25 |
| CR20250284A (en) | 2025-08-29 |
| KR20250124877A (en) | 2025-08-20 |
| US20240199761A1 (en) | 2024-06-20 |
| CO2025009742A2 (en) | 2025-08-08 |
| AR131398A1 (en) | 2025-03-12 |
| MX2025007229A (en) | 2025-07-01 |
| WO2024133161A1 (en) | 2024-06-27 |
| TW202444762A (en) | 2024-11-16 |
| CN120476150A (en) | 2025-08-12 |
| AU2023413552A1 (en) | 2025-07-31 |
| EP4638507A1 (en) | 2025-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4525871A4 (en) | Treatment of depression | |
| IL315503A (en) | Methods of treatment | |
| IL320711A (en) | Methods of treatment | |
| GB2618915B (en) | Treatment of cardiovascular disease | |
| IL299695B1 (en) | Treatment of cancer, inflammatory diseases and autoimmune diseases | |
| GB202001353D0 (en) | Treatment of skin conditions | |
| GB202109021D0 (en) | Treatment for autoimmune diseases | |
| IL327357A (en) | Combination treatment of autoimmune disorders | |
| GB202201824D0 (en) | Methods of treatment | |
| AU2021343534A9 (en) | TREATMENT OF NF-κB-MEDIATED DISEASE | |
| CA3277572A1 (en) | Treatment of autoimmune disease | |
| GB202201825D0 (en) | Methods of treatment | |
| GB202201819D0 (en) | Methods of treatment | |
| IL291626A (en) | Treatment of celiac disease | |
| GB202206353D0 (en) | Treatment of cervical dystonia | |
| IL307459A (en) | Treatment of kidney diseases | |
| GB202404416D0 (en) | Treatment of disease | |
| GB202315831D0 (en) | Treatment of skin disease | |
| IL326388A (en) | Macrocycles for the treatment of autoimmune diseases | |
| GB202102257D0 (en) | Treatment of shells | |
| GB202312427D0 (en) | Treatment for autoimmune disease | |
| GB202206359D0 (en) | Treatment of pain | |
| GB202315695D0 (en) | TReatment of cariomyopathy | |
| GB202212506D0 (en) | Treatment of covid-19 | |
| GB202116795D0 (en) | Treatment of visceral pain |